Who are Intranasal glugagon's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Carnitor, Isindone, Ativan, PERHEXILINE, Ferric Carboxymaltose (FCM), Triferic AVNU.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intranasal-glugagon.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Intranasal glugagon — Competitive Intelligence Brief

Intranasal glugagon (Intranasal glugagon) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormonal. Area: Metabolic.

marketed Hormonal Liver Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Intranasal glugagon (Intranasal glugagon) — A.O.U. Città della Salute e della Scienza.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intranasal glugagon TARGET	Intranasal glugagon	A.O.U. Città della Salute e della Scienza	marketed	Hormonal	Liver
Carnitor	LEVOCARNITINE	Leadiant Biosci Inc	marketed	Carnitine Analog [EPC]	Carnitine O-palmitoyltransferase 1, liver isoform	1985-01-01
Isindone	INDOPROFEN		marketed	indoprofen	Pyruvate kinase PKM, Fatty acid-binding protein, liver, Luciferin 4-monooxygenase	1979-01-01
Ativan	lorazepam	Generic (originally Wyeth/Pfizer)	marketed	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver	1977-09-30
PERHEXILINE	PERHEXILINE		marketed	perhexiline	Carnitine O-palmitoyltransferase 1, liver isoform, Carnitine O-palmitoyltransferase 2, mitochondrial, Cytochrome P450 2D6	1974-01-01
Ferric Carboxymaltose (FCM)	Ferric Carboxymaltose (FCM)	American Regent, Inc.	marketed	Intravenous iron replacement agent	Iron (Fe³⁺) delivery; transferrin and ferritin binding
Triferic AVNU	Triferic AVNU	Rockwell Medical Technologies, Inc.	marketed	Iron replacement agent	Iron (Fe3+) delivery system

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-01-08 — Ativan · 8999393 · Formulation · US

Sponsor landscape (Hormonal class)

A.O.U. Città della Salute e della Scienza · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intranasal glugagon — Competitive Intelligence Brief. https://druglandscape.com/ci/intranasal-glugagon. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab